基于模型的依曲莫德剂量优化:跨CYP2C9基因型与肝损伤的溃疡性结肠炎用药
研究用生理药代动力学模型预测依曲莫德在CYP2C9多态性和肝损伤的中国患者中的暴露变化,模型预测参数多数在2倍误差内,CYP2C9慢代谢者合并Child-Pugh C肝损伤时AUCss增加67%,支持多数受影响亚组减至1.5 mg每日一次、该人群减至1 mg每日一次。
要点
- CYP2C9多态性和肝损伤均增加依曲莫德暴露,二者合并时暴露升高最显著。
- CYP2C9慢代谢者合并Child-Pugh C肝损伤时AUCss增加67%。
- 模型支持多数受影响亚组减至1.5 mg每日一次,该人群减至1 mg每日一次。
核心结论
- CYP2C9多态性和肝损伤可增加依曲莫德暴露,尤其二者并存时暴露升高更明显。
- 基于模型暴露匹配支持对多数受影响亚组减至1.5 mg每日一次,CYP2C9慢代谢者合并Child-Pugh C肝损伤减至1 mg每日一次。
研究设计与样本
- 建立并验证生理药代动力学模型,验证数据包括体外代谢、单次给药、多次给药和药物相互作用临床药代动力学数据。
- 将验证模型外推至不同CYP2C9基因型和肝损伤严重程度的中国人群,表征暴露变化并优化给药方案。
主要发现
- 多数预测药代动力学参数在2倍误差范围内。
- 获批剂量2 mg每日一次时,白人受试者预测稳态AUC0-24中位数为1976.95 ng·h/mL(95%预测区间[PI]:975.78-4144.29 ng·h/mL),Cmax为98.40 ng/mL(95% PI:52.9-190.51 ng/mL)。
- 中国受试者预测稳态AUC0-24中位数为1988.82 ng·h/mL(95% PI:814.91-4244.10 ng·h/mL),Cmax为105.18 ng/mL(95% PI:51.30-198.03 ng/mL)。
- 中国人群中肝损伤和CYP2C9多态性均增加依曲莫德暴露,CYP2C9慢代谢者合并Child-Pugh C肝损伤时AUCss增加67%。
关键数值与推荐
- 多数受影响亚组:减至1.5 mg每日一次。
- CYP2C9慢代谢者合并Child-Pugh C肝损伤:减至1 mg每日一次。
临床怎么用
- 临床可为CYP2C9基因型和肝损伤状态不同的中国溃疡性结肠炎患者参考模型预测的剂量调整策略。
- 对CYP2C9慢代谢者合并Child-Pugh C肝损伤患者,可考虑减至1 mg每日一次。
- 对多数其他受影响亚组,可考虑减至1.5 mg每日一次。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Etrasimod is an oral sphingosine-1-phosphate receptor modulator approved for moderate-to-severe ulcerative colitis. The impact of CYP2C9 polymorphisms and hepatic impairment on etrasimod exposure remains unclear. This study aimed to characterize their effects and identify clinically relevant dose adjustment strategies in Chinese patients. METHODS: A physiologically based pharmacokinetic model was developed and verified using in vitro metabolism and single-dose, multiple-dose and drug-drug interaction clinical pharmacokinetic data. The validated model was extrapolated to Chinese populations with different CYP2C9 genotypes and hepatic impairment severity to characterize exposure changes and optimize dosing. RESULTS: Most predicted pharmacokinetic parameters are within a twofold error range. At the approved dose of 2 mg once daily, the predicted median steady-state AUC0-24 and Cmax were 1976.95 ng·h/mL (95% prediction interval [PI]: 975.78-4144.29 ng·h/mL) and 98.40 ng/mL (95% PI: 52.9-190.51 ng/mL) in Caucasian subjects and 1988.82 ng·h/mL (95% PI: 814.91-4244.10 ng·h/mL) and 105.18 ng/mL (95% PI: 51.30-198.03 ng/mL) in Chinese subjects, respectively. In Chinese populations, hepatic impairment and CYP2C9 polymorphisms increased etrasimod exposure, with the greatest increase observed in CYP2C9 poor metabolizers with Child-Pugh C hepatic impairment (67% increase in AUCss). CONCLUSIONS: CYP2C9 polymorphisms and hepatic impairment increased etrasimod exposure, particularly when combined. Model-based exposure matching supported dose reduction to 1.5 mg once daily for most affected subgroups and to 1 mg once daily for CYP2C9 poor metabolizers with Child-Pugh C hepatic impairment, providing quantitative support for individualized dosing.
引用
- Xu Z, Qian F, Liu Y, et al. Model-informed dose optimization of etrasimod in ulcerative colitis across CYP2C9 genotypes and hepatic impairment. Br J Clin Pharmacol. 2026. PMID: 42610655. doi:10.1002/bcp.70777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。